Network meta- analysis revealed that in adolescents , intervention with 2000 mg/day metformin ranked better than other interventions ; however , 1000 mg/day metformin for 3 months may be most suitable for adolescents .
For adults , metformin at doses of 3000 and 1000 mg/day ranked the highest , other than minimeal and lifestyle interventions ; moreover , intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults .
Conclusion When considering the efficacy of interventions for losing weight , metformin offers clear advantages for overweight and obese population
Purpose Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta- analysis and to identify the most suitable dosage and intervention period for using metformin  in adolescents and adults .
Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-Naïve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial
Introduction The aim of this study was to investigate the efficacy and safety of linagliptin + low-dose ( LD ) metformin once daily versus high-dose ( HD ) metformin twice daily in treatment-naïve patients with type 2 diabetes . Methods Patients ( n = 689 ) were r and omized ( 1:1 ) to double-blind treatment with linagliptin 5 mg + LD metformin ( 1000 mg ) or HD metformin ( 2000 mg ) for 14 weeks . Metformin was initiated at 500 mg/day and up-titrated within 2 weeks ; the dose then remained unchanged . The primary endpoint was change in glycated hemoglobin ( HbA1c ) from baseline to Week 14 in patients who tolerated a daily metformin dose of ≥1000 mg after 2 weeks . Results At Week 14 , HbA1c changed from a mean baseline of 8.0 % ( 64 mmol/mol ) by −0.99 % ( −11 mmol/mol ) for linagliptin + LD metformin , and −0.98 % ( −11 mmol/mol ) for HD metformin [ treatment difference −0.01 % ( 95 % confidence interval −0.13 , 0.12 ) ( 0 mmol/mol ) , P = 0.8924 ] . The proportion of patients who achieved HbA1c < 7.0 % ( 53 mmol/mol ) without occurrence of moderate or severe gastrointestinal ( GI ) events ( including abdominal pain , nausea , vomiting , diarrhea , and decreased appetite ) was the same in both groups ( 51.3 % for both ) . Although the occurrence of moderate or severe GI events was similar , the linagliptin + LD metformin group had fewer mild GI events ( 18.5 % versus 24.3 % ) . The incidence of hypoglycemia was low in both groups . Conclusion Linagliptin + LD metformin combination showed similar efficacy and  safety to HD metformin . This combination may be an alternative treatment option in patients who may have difficulty tolerating  metformin doses > 1000 mg/day . Funding Boehringer Ingelheim
Network meta- analysis revealed that in adolescents , intervention with 2000 mg/day metformin ranked better than other interventions ; however , 1000 mg/day metformin for 3 months may be most suitable for adolescents .
For adults , metformin at doses of 3000 and 1000 mg/day ranked the highest , other than minimeal and lifestyle interventions ; moreover , intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults .
Conclusion When considering the efficacy of interventions for losing weight , metformin offers clear advantages for overweight and obese population
Purpose Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta- analysis and to identify the most suitable dosage and intervention period for using metformin  in adolescents and adults .